Ireland-based clinical research organisation giant Icon has completed its $143.5 million acquisition of Aptiv Solutions. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/icon_seals_acquisition_of_aptiv_1001917Regulators in Europe have followed the example of their counterparts across the Atlantic and expanded approval on Celgene’s big-selling multiple myeloma drug Revlimid to include newly-diagnosed patients. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/celgene_gets_revlimid_boost_in_europe_971074Roche’s leukaemia drug Gazyva has shown significant benefit in a late-stage trial for refractory indolent non-Hodgkin’s lymphoma, meeting its primary endpoint early. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/roche_leukaemia_drug_gazyva_succeeds_in_lymphoma_970994UCB has acquired the key pharmaceutical assets of the UK's Lectus Therapeutics, boosting its efforts in the central nervous system field. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ucb_acquires_lectus_assets_980012The European Commission has given the green light to Newron Pharmaceuticals of Italy’s Parkinson’s disease drug Xadago. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/newron_parkinsons_drug_xadago_gets_europe_okay_971112Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ferring_buys_biosets_orthobiologics_971064Eli Lilly has entered into a collaboration with Japan's PeptiDream to discover and develop novel therapeutic peptides. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/lilly_links_up_with_japans_peptidream_1006215Shire’s good run is continuing with the news that the US Food and Drug Administration has granted fast-track designation for SHP609 (idursulfase-IT) for the treatment of neurocognitive decline associated with Hunter syndrome. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/usa_fast-tracks_shire_hunter_syndrome_drug_970931The European Medicines Agency says it has been notified by Vanda Pharmaceuticals of the USA that it wants to withdraw its application for the schizophrenia drug Fanaptum (iloperidone) intended to be used for the treatment of schizophrenia. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/vanda_pulls_eu_filing_for_schizophrenia_drug_1004648Actavis will pull out of China because it is not "worth the aggravation", chief executive Paul Bisaro has told Bloomberg. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/actavis_to_pull_out_of_china_1001367
